{"filing":{"accession_number":"0001213900-26-086933","cik":"0000907654","ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"ea0301312-8k_oruka.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/907654/000121390026086933/ea0301312-8k_oruka.htm"},"events":[{"id":26329,"run_id":23921,"accession_number":"0001213900-26-086933","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a straightforward earnings release for Q2 2026 financial results. The Item 2.02 disclosure explicitly states that \"Oruka Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated balance sheets and statements of operations showing Q2 2026 results (net loss of $41.2 million vs. $24.6 million in Q2 2025) along with a corporate update on pipeline progress.","company_name":"Oruka Therapeutics, Inc.","ticker":"ORKA","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27413,"accession_number":"0001213900-26-086933","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a straightforward earnings release for Q2 2026 financial results. The Item 2.02 disclosure explicitly states that \"Oruka Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated balance sheets and statements of operations showing Q2 2026 results (net loss of $41.2 million vs. $24.6 million in Q2 2025) along with a corporate update on pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:03:03.699056+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27413,"accession_number":"0001213900-26-086933","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a straightforward earnings release for Q2 2026 financial results. The Item 2.02 disclosure explicitly states that \"Oruka Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated balance sheets and statements of operations showing Q2 2026 results (net loss of $41.2 million vs. $24.6 million in Q2 2025) along with a corporate update on pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:03:03.699056+00:00","company_name":"Oruka Therapeutics, Inc.","ticker":"ORKA","filing_date":"2026-08-10"}]}